Quince Therapeutics, Inc.
QNCX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001662774
No open-market purchases or sales by Quince Therapeutics, Inc. insiders were filed in the last 90 days; 26 institutions reported holding it in 13F filings for Q2 2026, worth $4.74M in total; no superinvestor holds it.
Holders of 5% or more of QNCX
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Quince Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Group One Trading, L.P. | 13G | 10.70%5.94M shares | New | Mar 5, 20261 filing | Mar 5, 2026 | SEC |
| Cormorant Asset Management, LP | 13G | 9.99%108.0K shares | New | Aug 14, 20261 filing | Aug 14, 2026 | SEC |
| Balyasny Asset Management LLC | 13G | 9.99%97.7K shares | New | Aug 14, 20261 filing | Aug 14, 2026 | SEC |
| Ikarian Capital, LLC | 13G | 9.00%91.8K shares | New | Aug 14, 20261 filing | Aug 14, 2026 | SEC |
| Integrated Core Strategies (US) LLC | 13G | 7.20%1.40M shares | New | Jun 10, 20261 filing | Jun 10, 2026 | SEC |
| Squadron Capital Management LLC | 13G | 5.60%55.2K shares | New | Aug 4, 20261 filing | Aug 4, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
42 Schedule 13D and 13G filings on Quince Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Aug 14, 20269:20 PM ET | Ikarian Capital, LLCand 1 other | 13G | 9.00%91.8K shares | New | Jun 30, 2026 | SEC |
| Aug 14, 20264:44 PM ET | Nantahala Capital Management, LLCand 2 others | 13G/A | 0.00%0 shares | −7.52 ppfrom 7.52%Below 5% | Jun 30, 2026 | SEC |
| Aug 14, 20262:05 PM ET | Cormorant Asset Management, LPand 1 other | 13G | 9.99%108.0K shares | New | Jun 30, 2026 | SEC |
| Aug 14, 20266:07 AM ET | Balyasny Asset Management LLCand 4 others | 13G | 9.99%97.7K shares | New | Jun 30, 2026 | SEC |
| Aug 4, 20263:06 PM ET | Squadron Capital Management LLCand 3 others | 13G | 5.60%55.2K shares | New | Jul 28, 2026 | SEC |
| Jun 10, 20264:38 PM ET | Integrated Core Strategies (US) LLCand 3 others | 13G | 7.20%1.40M shares | New | Jun 4, 2026 | SEC |
| May 15, 20264:38 PM ET | Nantahala Capital Management, LLCand 2 others | 13G/A | 7.52%4.53M shares | −2.47 ppfrom 9.99% | Mar 31, 2026 | SEC |
| Mar 5, 20265:52 PM ET | Group One Trading, L.P. | 13G | 10.70%5.94M shares | New | Feb 28, 2026 | SEC |
| Nov 14, 20254:32 PM ET | Nantahala Capital Management, LLCand 2 others | 13G/A | 9.99%5.62M shares | 0.00 ppfrom 9.99% | Sep 30, 2025 | SEC |
| Oct 30, 20252:29 PM ET | Genextra S.p.A.and 2 others | 13G/A | 0.00%0 shares | −6.49 ppfrom 6.49%Below 5% | Jul 7, 2025 | SEC |
| Aug 14, 20254:33 PM ET | Nantahala Capital Management, LLCand 2 others | 13G | 9.99%4.77M shares | New | Jun 30, 2025 | SEC |
| Apr 30, 20254:06 PM ET | Sofinnova Partners SASand 7 others | 13G/A | 2.70%1.20M shares | −2.70 ppfrom 5.40%Below 5% | Mar 31, 2025 | SEC |
| Feb 18, 20251:46 PM ET | Genextra S.p.A.and 2 others | 13G/A | 6.49%2.81M shares | – | Oct 18, 2024 | SEC |
| Feb 14, 20254:29 PM ET | Sofinnova Partners SASand 7 others | 13G | 5.40%2.40M shares | – | Dec 31, 2024 | SEC |
| Nov 14, 2024 | Tang Capital Management LLC | 13G/AOld format | – | – | – | SEC |
| Nov 13, 2024 | Lamond David | 13DOld format | – | – | – | SEC |
| Aug 6, 2024 | Sofinnova Partners SAS | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2024 | Tang Capital Partners LP | 13G/AOld format | – | – | – | SEC |
| Feb 12, 2024 | Sofinnova Partners SAS | 13GOld format | – | New | – | SEC |
| Feb 7, 2024 | BML Investment Partners, L.P. | 13G/AOld format | – | – | – | SEC |
| Dec 15, 2023 | Genextra S.p.A. | 13GOld format | – | New | – | SEC |
| Jul 17, 2023 | BML Investment Partners, L.P. | 13GOld format | – | New | – | SEC |
| Mar 31, 2023 | Tang Capital Partners LP | 13GOld format | – | New | – | SEC |
| Feb 13, 2023 | Epq LLC, Ctym PS | 13G/AOld format | – | – | – | SEC |
| Jul 8, 2022 | Capital World Investors | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2022 | Pfizer Inc | 13G/AOld format | – | – | – | SEC |
| Feb 11, 2022 | Capital World Investors | 13G/AOld format | – | – | – | SEC |
| Feb 11, 2022 | Capital Research Global Investors | 13G/AOld format | – | – | – | SEC |
| Dec 10, 2021 | Capital International Investors | 13G/AOld format | – | – | – | SEC |
| Dec 10, 2021 | Capital International Investors | 13G/AOld format | – | – | – | SEC |
| Oct 8, 2021 | Capital International Investors | 13G/AOld format | – | – | – | SEC |
| Oct 8, 2021 | Capital International Investors | 13G/AOld format | – | – | – | SEC |
| Apr 27, 2021 | Lamond David | 13G/AOld format | – | – | – | SEC |
| Mar 25, 2021 | Pfizer Inc | 13G/AOld format | – | – | – | SEC |
| Mar 10, 2021 | Capital World Investors | 13G/AOld format | – | – | – | SEC |
| Feb 16, 2021 | Capital International Investors | 13GOld format | – | – | – | SEC |
| Feb 16, 2021 | Capital International Investors | 13GOld format | – | New | – | SEC |
| Feb 16, 2021 | Capital World Investors | 13GOld format | – | New | – | SEC |
| Feb 16, 2021 | Capital Research Global Investors | 13G/AOld format | – | – | – | SEC |
| Feb 16, 2021 | Pfizer Inc | 13G/AOld format | – | – | – | SEC |
| Feb 1, 2021 | Epq LLC, Ctym PS | 13G/AOld format | – | – | – | SEC |
| Jan 29, 2021 | Takeda Pharmaceutical Co Ltd | 13G/AOld format | – | – | – | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Quince Therapeutics, Inc. shares.
No Form 144 notices for Quince Therapeutics, Inc. are on file.